Iodine induces apoptosis via regulating MAPKs-related p53, p21, and Bcl-xL in thyroid cancer cells

Molecular and Cellular Endocrinology

Volumn 320, Issue 1-2, 2010, Pages 128-135

  Liu, Xiao Hong ^a   Chen, George G ^a   Vlantis, Alexander C ^a   Tse, Gary M ^a   van Hasselt, C Andrew ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; Bcl xL; Iodine; MAPKs; P21; P53; Thyroid cancer

Indexed keywords

IODINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL XL; PROTEIN P21; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE 1;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MUTANT; PRIORITY JOURNAL; REGULATORY MECHANISM; RNA INTERFERENCE; THYROID CANCER; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOPROTECTION; ENZYME ACTIVATION; HUMANS; IODINE; MAP KINASE SIGNALING SYSTEM; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 77949568523     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.02.004     Document Type: Article

References (37)

1. Are C., Shaha A.R. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann. Surg. Oncol. 2006, 13:453-464.
2. Bai J., Sui J., Demirjian A., Vollmer C.M., Marasco W., Callery M.P. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res. 2005, 65:2344-2352.
3. Burgess J.R., Dwyer T., McArdle K., Tucker P., Shugg D. The changing incidence and spectrum of thyroid carcinoma in Tasmania (1978-1998) during a transition from iodine sufficiency to iodine deficiency. J. Clin. Endocrinol. Metab. 2000, 85:1513-1517.
4. Catalano M.G., Pugliese M., Poli R., Bosco O., Bertieri R., Fortunati N., Boccuzzi G. Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib. Oncol. Rep. 2009, 21:515-521.
5. Dal Maso L., Bosetti C., La Vecchia C., Franceschi S. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control 2009, 20:75-86.
6. Dijkstra B., Prichard R.S., Lee A., Kelly L.M., Smyth P.P., Crotty T., McDermott E.W., Hill A.D., O'Higgins N. Changing patterns of thyroid carcinoma. Ir. J. Med. Sci. 2007, 176:87-90.
7. Fagin J.A., Matsuo K., Karmakar A., Chen D.L., Tang S.H., Koeffler H.P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. 1993, 91:179-184.
8. -) treatment Evidence that I2 prevents cancer promotion. Mol. Cell Endocrinol. 2005, 236:49-57.
9. Gartel A.L., Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. 2002, 1:639-649.
10. Herr I., Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood 2001, 98:2603-2614.
11. Ho Y.S., Tseng S.C., Chin T.Y., Hsieh L.L., Lin J.D. p53 gene mutation in thyroid carcinoma. Cancer Lett. 1996, 103:57-63.
12. Ito T., Seyama T., Mizuno T., Tsuyama N., Hayashi T., Hayashi Y., Dohi K., Nakamura N., Akiyama M. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 1992, 52:1369-1371.
13. Jung K.H., Paik J.Y., Ko B.H., Lee K.H. Mitogen-activated protein kinase signaling enhances sodium iodide symporter function and efficacy of radioiodide therapy in nonthyroidal cancer cells. J. Nucl. Med. 2008, 49:1966-1972.
14. Krohn K., Maier J., Paschke R. Mechanisms of disease: hydrogen peroxide. DNA damage and mutagenesis in the development of thyroid tumors. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3:713-720.
15. Li M., Lee T.W., Yim A.P., Mok T.S., Chen G.G. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells. J. Cell. Physiol. 2006, 209:428-438.
16. Liste I., Garcia-Garcia E., Bueno C., Martinez-Serrano A. Bcl-XL modulates the differentiation of immortalized human neural stem cells. Cell Death Differ. 2007, 14:1880-1892.
17. Liu Z., Hou P., Ji M., Guan H., Studeman K., Jensen K., Vasko V., El-Naggar A.K., Xing M. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J. Clin. Endocrinol. Metab. 2008, 93:3106-3116.
18. Maier J., van Steeg H., van Oostrom C., Paschke R., Weiss R.E., Krohn K. Iodine deficiency activates antioxidant genes and causes DNA damage in the thyroid gland of rats and mice. Biochim. Biophys. Acta 2007, 1773:990-999.
19. Martinez-Brocca M.A., Castilla C., Navarro E., Amaya M.J., Travado P., Japon M.A., Saez C. Clinicopathological correlations of Bcl-xL and Bax expression in differentiated thyroid carcinoma. Clin. Endocrinol. (Oxf.) 2008, 68:190-197.
20. Nagayama Y., Yokoi H., Takeda K., Hasegawa M., Nishihara E., Namba H., Yamashita S., Niwa M. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J. Clin. Endocrinol. Metab. 2000, 85:4081-4086.
21. Osaki M., Oshimura M., Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9:667-676.
22. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell 2003, 3:17-22.
23. Schlumberger M., Lacroix L., Russo D., Filetti S., Bidart J.M. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3:260-269.
24. She Q.B., Bode A.M., Ma W.Y., Chen N.Y., Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res. 2001, 61:1604-1610.
25. Shoemaker A.R., Oleksijew A., Bauch J., Belli B.A., Borre T., Bruncko M., Deckwirth T., Frost D.J., Jarvis K., Joseph M.K., et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res. 2006, 66:8731-8739.
26. Shrivastava A., Tiwari M., Sinha R.A., Kumar A., Balapure A.K., Bajpai V.K., Sharma R., Mitra K., Tandon A., Godbole M.M. Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway. J. Biol. Chem. 2006, 281:19762-19771.
27. Smallridge R.C., Marlow L.A., Copland J.A. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer 2009, 16:17-44.
28. Smyth P.P. Role of iodine in antioxidant defence in thyroid and breast disease. Biofactors 2003, 19:121-130.
29. Stassi G., Todaro M., Zerilli M., Ricci-Vitiani L., Di Liberto D., Patti M., Florena A., Di Gaudio F., Di Gesu G., De Maria R. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res. 2003, 63:6784-6790.
30. Vitale M., Di Matola T., D'Ascoli F., Salzano S., Bogazzi F., Fenzi G., Martino E., Rossi G. Iodide excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress. Endocrinology 2000, 141:598-605.
31. Wada T., Penninger J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004, 23:2838-2849.
32. Wang M.Y., Chen P.S., Prakash E., Hsu H.C., Huang H.Y., Lin M.T., Chang K.J., Kuo M.L. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res. 2009, 69:3482-3491.
33. Whibley C., Pharoah P.D., Hollstein M. p53 polymorphisms: cancer implications. Nat. Rev. Cancer 2009, 9:95-107.
34. Willis A., Jung E.J., Wakefield T., Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004, 23:2330-2338.
35. Wong R.P., Tsang W.P., Chau P.Y., Co N.N., Tsang T.Y., Kwok T.T. p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol. Cancer Ther. 2007, 6:1054-1061.
36. Xiao X., Ning L., Chen H. Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors. Mol. Cancer Ther. 2009, 8:350-356.
37. Yang H.L., Pan J.X., Sun L., Yeung S.C. p21 Waf-1 (Cip-1) enhances apoptosis induced by manumycin and paclitaxel in anaplastic thyroid cancer cells. J. Clin. Endocrinol. Metab. 2003, 88:763-772.